10 research outputs found
Endoplasmic reticulum chaperone prolyl 4-hydroxylase, beta polypeptide (P4HB) promotes malignant phenotypes in glioma via MAPK signaling
Get PDFpublished_or_final_versio
Demographic and Outcome of Ependymoma: A Single Center Study
No full textFree Paper Sessions (Poster) P5
Outcome comparison between younger and older patients undergoing intracranial meningioma resections
No full textOutcome of elderly patients undergoing intracranial meningioma resection – a systematic review and meta-analysis
No full textReview of Surgical Outcome of Skull Base Meningioma in a Single Institute Based on ABC Surgical Risk Scale
No full textFree Paper Sessions (Oral & Oral Poster) FP2-O1
Primary CNS NK-cell lymphoma in a Chinese woman with atypical C11-choline PET and MR spectrometry findings
No full textCRNDE Expression Positively Correlates with EGFR Activation and Modulates Glioma Cell Growth
No full textRutin increases the cytotoxicity of temozolomide in glioblastoma via autophagy inhibition
No full text
The Use of Tranexamic Acid for Traumatic Brain Injury with Contusions or Traumatic Subarachnoid Haemorrhage in the Elderly
No full textObjective:
To investigate the impact of Tranexamic Acid (TXA) as an initial non-operative treatment on the mortality rate of traumatic brain injury with contusions or traumatic subarachnoid haemorrhage in the elderly.
Method:
This was a seven-year retrospective study of consecutive patients admitted for traumatic brain injury with contusions or traumatic subarachnoid haemorrhage at Queen Mary Hospital from 2010-2016. Primary outcome was the overall mortality rate. Secondary outcomes included rate of deterioration requiring operation and the survival rate without operations.
Result:
In total 651 consecutive patients were identified. 81 patients had TXA (TXA group) while 570 did not have TXA (control group) during admission. The average age was 73.92 years old (95%CI 68.77-77.84 years old) for the TXA group versus 65.36 years old (95%CI 63.24-67.48 years old) for the control group (p=0.0062). The overall mortality rate with TXA was 7.40% versus 8.77% in the control group (OR 0.832 95%CI 0.345-2.007, p=0.682). The rate of deterioration requiring operation in the TXA group was 6.17% versus 16.3% in the control group (OR 0.337 95%CI 0.133-0.857, p=0.022). The survival rate with no operations in the TXA group was 88.89% versus 77.89% in the control group (OR 2.270 95%CI 1.104-4.667, p=0.026).
Conclusion:
In this study, patients in the TXA group was significantly older than that in the control group. The overall mortality rates were comparable in the two groups. The TXA group had a lower rate of operation. With the use of Tranexamic Acid, there were significantly more survivors without operations
